Cyclerion Therapeutics Stock Analysis
CYCN Stock | USD 2.77 0.28 9.18% |
Cyclerion Therapeutics is undervalued with Real Value of 3.28 and Target Price of 4.0. The main objective of Cyclerion Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Cyclerion Therapeutics is worth, separate from its market price. There are two main types of Cyclerion Therapeutics' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Cyclerion Therapeutics' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Cyclerion Therapeutics' stock to identify patterns and trends that may indicate its future price movements.
The Cyclerion Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Cyclerion Therapeutics is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Cyclerion Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Cyclerion Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
Cyclerion |
Cyclerion Stock Analysis Notes
About 21.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.81. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cyclerion Therapeutics recorded a loss per share of 5.39. The entity had not issued any dividends in recent years. The firm had 1:20 split on the 16th of May 2023. Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system diseases. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Cyclerion Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 32 people. For more info on Cyclerion Therapeutics please contact Peter Hecht at 857 327 8778 or go to https://www.cyclerion.com.Cyclerion Therapeutics Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Cyclerion Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Cyclerion Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Cyclerion Therapeutics had very high historical volatility over the last 90 days | |
Cyclerion Therapeutics has a very high chance of going through financial distress in the upcoming years | |
Net Loss for the year was (5.26 M) with loss before overhead, payroll, taxes, and interest of (29.75 M). | |
Cyclerion Therapeutics currently holds about 30.32 M in cash with (21.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.7. | |
Cyclerion Therapeutics has a poor financial position based on the latest SEC disclosures | |
Roughly 21.0% of the company shares are held by company insiders | |
Latest headline from MacroaxisInsider: Acquisition by Peter Hecht of 430000 shares of Cyclerion Therapeutics at 1.21 subject to Rule 16b-3 |
Cyclerion Therapeutics Upcoming and Recent Events
Earnings reports are used by Cyclerion Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cyclerion Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
27th of March 2024 Upcoming Quarterly Report | View | |
31st of December 2023 Next Fiscal Quarter End | View |
Cyclerion Largest EPS Surprises
Earnings surprises can significantly impact Cyclerion Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2022-02-24 | 2021-12-31 | -0.3 | -0.33 | -0.03 | 10 | ||
2022-05-04 | 2022-03-31 | -0.36 | -0.3 | 0.06 | 16 | ||
2022-11-03 | 2022-09-30 | -0.31 | -0.24 | 0.07 | 22 |
Cyclerion Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cyclerion Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cyclerion Therapeutics backward and forwards among themselves. Cyclerion Therapeutics' institutional investor refers to the entity that pools money to purchase Cyclerion Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Group One Trading, Lp | 2023-12-31 | 540 | Royal Bank Of Canada | 2023-12-31 | 330 | Advisor Group Holdings, Inc. | 2023-12-31 | 187 | Wells Fargo & Co | 2023-12-31 | 15.0 | Northwestern Mutual Wealth Management Co | 2023-12-31 | 1.0 | Captrust Financial Advisors | 2023-09-30 | 0.0 | Acadian Asset Management Llc | 2023-12-31 | 0.0 | Jane Street Group, Llc | 2023-09-30 | 0.0 | Rhumbline Advisers | 2023-12-31 | 0.0 | Slate Path Capital Lp | 2023-12-31 | 357.9 K | Mfn Partners Management, Lp | 2023-12-31 | 169.5 K |
Cyclerion Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 7.51 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cyclerion Therapeutics's market, we take the total number of its shares issued and multiply it by Cyclerion Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Cyclerion Profitablity
Cyclerion Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Cyclerion Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Cyclerion Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Cyclerion Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Cyclerion Therapeutics' profitability requires more research than a typical breakdown of Cyclerion Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (1.57) | (1.65) | |
Return On Capital Employed | (0.85) | (0.81) | |
Return On Assets | (1.57) | (1.65) | |
Return On Equity | (1.86) | (1.77) |
Management Efficiency
Cyclerion Therapeutics has return on total asset (ROA) of (0.3834) % which means that it has lost $0.3834 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1585) %, meaning that it created substantial loss on money invested by shareholders. Cyclerion Therapeutics' management efficiency ratios could be used to measure how well Cyclerion Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of April 2024, Return On Tangible Assets is likely to drop to -1.65. In addition to that, Return On Capital Employed is likely to grow to -0.81. At this time, Cyclerion Therapeutics' Non Currrent Assets Other are very stable compared to the past year. As of the 25th of April 2024, Asset Turnover is likely to grow to 0.02, while Total Assets are likely to drop about 12.7 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | 4.83 | 4.59 | |
Net Current Asset Value | 0.00 | 0.00 | |
Tangible Asset Value | 0.00 | 0.00 | |
Tangible Book Value Per Share | 4.83 | 4.59 | |
Enterprise Value Over EBITDA | (0.03) | (0.03) | |
Price Book Value Ratio | 0.69 | 0.73 | |
Enterprise Value Multiple | (0.03) | (0.03) | |
Price Fair Value | 0.69 | 0.73 | |
Enterprise Value | 0.00 | 0.00 |
The analysis of Cyclerion Therapeutics' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Cyclerion Therapeutics' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Cyclerion Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 1.83 |
Technical Drivers
As of the 25th of April, Cyclerion Therapeutics shows the mean deviation of 4.49, and Risk Adjusted Performance of 0.0015. Cyclerion Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down thirteen technical drivers for Cyclerion Therapeutics, which can be compared to its peers. Please confirm Cyclerion Therapeutics market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if Cyclerion Therapeutics is priced correctly, providing market reflects its regular price of 2.77 per share. Please also double-check Cyclerion Therapeutics jensen alpha, which is currently at (0.05) to validate the company can sustain itself at a future point.Cyclerion Therapeutics Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Cyclerion Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Cyclerion Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Cyclerion Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cyclerion Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cyclerion Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cyclerion Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cyclerion Therapeutics Predictive Daily Indicators
Cyclerion Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Cyclerion Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Daily Balance Of Power | (9,223,372,036,855) | |||
Rate Of Daily Change | 0.91 | |||
Day Median Price | 2.77 | |||
Day Typical Price | 2.77 | |||
Price Action Indicator | (0.14) | |||
Period Momentum Indicator | (0.28) |
Cyclerion Therapeutics Corporate Filings
8K | 18th of April 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 11th of March 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
10K | 5th of March 2024 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
13A | 14th of February 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 9th of February 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 26th of January 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 22nd of January 2024 An amended filing to the original Schedule 13G | ViewVerify |
F3 | 11th of December 2023 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Cyclerion Therapeutics Forecast Models
Cyclerion Therapeutics' time-series forecasting models are one of many Cyclerion Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cyclerion Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Cyclerion Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Cyclerion Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cyclerion shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Cyclerion Therapeutics. By using and applying Cyclerion Stock analysis, traders can create a robust methodology for identifying Cyclerion entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (170.67) | (162.14) | |
Operating Profit Margin | (171.81) | (163.22) | |
Net Loss | (169.53) | (161.06) | |
Gross Profit Margin | 0.78 | 0.90 |
Current Cyclerion Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Cyclerion analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Cyclerion analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
4.0 | Strong Buy | 1 | Odds |
Most Cyclerion analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Cyclerion stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Cyclerion Therapeutics, talking to its executives and customers, or listening to Cyclerion conference calls.
Cyclerion Stock Analysis Indicators
Cyclerion Therapeutics stock analysis indicators help investors evaluate how Cyclerion Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Cyclerion Therapeutics shares will generate the highest return on investment. By understating and applying Cyclerion Therapeutics stock analysis, traders can identify Cyclerion Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow | 13.4 M | |
Common Stock Shares Outstanding | 2.3 M | |
Total Stockholder Equity | 11.3 M | |
Cash And Short Term Investments | 7.6 M | |
Cash | 7.6 M | |
Accounts Payable | 1.2 M | |
Net Debt | -7.6 M | |
50 Day M A | 3.0984 | |
Total Current Liabilities | 2.1 M | |
Other Operating Expenses | 9.6 M | |
Non Current Assets Total | 5.3 M | |
Non Currrent Assets Other | 5.3 M | |
Stock Based Compensation | 1.1 M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclerion Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Cyclerion Stock, please use our How to Invest in Cyclerion Therapeutics guide.Note that the Cyclerion Therapeutics information on this page should be used as a complementary analysis to other Cyclerion Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Cyclerion Stock analysis
When running Cyclerion Therapeutics' price analysis, check to measure Cyclerion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclerion Therapeutics is operating at the current time. Most of Cyclerion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cyclerion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclerion Therapeutics' price. Additionally, you may evaluate how the addition of Cyclerion Therapeutics to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |
Is Cyclerion Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclerion Therapeutics. If investors know Cyclerion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclerion Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.39) | Revenue Per Share 0.586 | Quarterly Revenue Growth 0.141 | Return On Assets (0.38) | Return On Equity (1.16) |
The market value of Cyclerion Therapeutics is measured differently than its book value, which is the value of Cyclerion that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclerion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclerion Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclerion Therapeutics' market value can be influenced by many factors that don't directly affect Cyclerion Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclerion Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclerion Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclerion Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.